China’s national development and reform committee (NDRC), which oversees pricing across industries, has announced plans to introduce further mandated price cuts.
Dipexium Pharmaceuticals has successfully scaled-up API for its antimicrobial peptide phase III candidate Locilex, made from the skin of the African Clawed Frog.
The US FDA has ordered new labelling changes for immediate-release (IR) opioids but rejects claims that such products pose the same risks as extended-release (ER) opioids.
When pharmaceutical companies miss their capacity forecast, it is both costly and time consuming, so many are choosing to outsource in order to mitigate risks.
Drug companies should share more details of their APIs and the green credentials of the companies that supply says an award winning environmental researcher.
The partnership with recombinant protein development firm GTP Technologies will create an end-to-end manufacturing service, speeding up production of monoclonal antibodies and reducing costs, says Novasep.
The global contract and manufacturing organization (CDMO) announced the construction at a ground breaking ceremony held at its Ravensburg Schuetzenstrasse site.
Propanc Health Group Corporation has received $1.2m from an institutional investor in order to fast track preclinical activities for its lead product, PRP.
Drug companies were a more important source of revenue for Lonza in 2015 than in previous years with four of its five biggest spending customers coming from the pharmaceutical sector.
CSL Behring has opted to extend the half-life of its haemophilia B treatment Idelvion using a technology developed by Novozymes A/S subsidiary Albumedix.
Metrion Biosciences has been awarded a grant to develop CiPA-compliant stem cells and screening technologies by Eurostars, a European Union (EU) programme.
Zenith Technologies and SEA Vision have teamed up to offer drugmakers a service they say will bring “seamless compliance” to upcoming serialisation regulations.
BioPharmaSpec has set up business development teams for the Indian and Asia-Pacific markets and predicted increased demand for biosimilar characterisation services.
Covance has rolled out a consulting designed to help trial sponsors check that mobile apps they plan to use in clinical research meet with regulatory guidelines.
Compounds that leave pathogenic bacteria alive but harmless could yield antibiotics that are less likely to induce resistance development say the authors of a new study.
The slowdown in developing markets has prompted many pharmaceutical firms to focus on specialty drugs according to an IMS Health analyst, who predicted that the trend will accelerate.
The drug industry needs to rethink what defines a ‘high-risk’ candidate say an expert calling for more detailed pharmacological studies in the wake of the BIA 10-2474 tragedy.
The changeover time between batches is significantly quicker using disposable equipment, says Avid Bioservices whose new biomanufacturing facility boasts several 1,000L single-use bioreactors.
Lonza has launched a reformulated CHO media that it says supports the growth of higher density cultures and is easier to filter than currently available products.
Generic drugs in China must demonstrate bioequivalence (BE) to branded medicines under new CFDA rules prohibiting the use of locally-made generics as reference products.
Scientists in Europe have proposed a cost-effective way of monitoring chemicals in EU waters - including pharmaceuticals - using unmanned sampling devices.
Pfizer has said it will invest $21m to expand a plant in Adelaide, Australia which will manufacture a candidate biosimilar version of Amgen’s white blood cell booster, Neulasta.
Sanofi Pasteur, the vaccines division of Sanofi, has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.
An influenza vaccine produced in tobacco plants could make a big impact in the market if it reaches the market in the US in time for the 2018-19 flu season, says a market analyst.
